MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to ROS augmenting agents

Through a small scale metabolic-modulator screening, we have identified dimethyl fumarate (DMF), a FDA approved drug for multiple sclerosis, which suppresses neuroblastoma cell growth in vitro and in vivo. Mechanistically, DMF suppresses neuroblastoma cell growth through inducing ROS and subsequently suppressing MYCN expression.

6

Wang T, Liu L, Chen X, Shen Y, Lian G, Shah N, Davidoff AM, Yang J, Wang R